Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastomaJun Takei(Jikei University School of Medicine), Yasuharu Akasaki(Jikei University School of Medicine)Cancer Immunology ImmunotherapyJune 29, 202310.1007/s00262-023-03482-8Cited by 8SaveCiteExport RISWatch citationsRelated PapersA Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells|Journal of Biological Chemistry|2005|67